Glaxosmithkline plc (GSK) tapped Arrowhead Pharmaceuticals Inc. for its foray into nonalcoholic steatohepatitis (NASH), as the pair signed an exclusive global licensing deal (excluding China) for GSK to develop and commercialize phase I/II-stage ARO-HSD, Arrowhead’s RNAi therapy targeting HSD17B13.

PERTH, Australia – Australian researchers have debunked previous research that suggests autism spectrum disorder behavior may be caused by differences in the composition of the gut microbiota.

In contrast to most adult mammalian tissues, the liver can regenerate itself to an impressive degree. That regeneration is critical to survival – as a key digestive organ, the liver deals with all sorts of toxins, from rotten-ish food in the wild to alcohol in more cultured settings.